Supporting Information

Synthesis of ester-containing phenanthridines via photoredox-

catalyzed radical cascade cyclization of N-arylacrylamides with

alkyloxalyl chlorides

Meiling Chen,^a Jian-Qiang Chen,^b Zhengkai Chen*^a and Jie Wu*^{b,c,d}

^a Department of Chemistry, Key Laboratory of Surface & Interface Science of Polymer Materials of Zhejiang Province, Zhejiang Sci-Tech University, Hangzhou 310018, People's Republic of China.

^b School of Pharmaceutical and Chemical Engineering & Institute for Advanced Studies, Taizhou University, Taizhou 318000, China.

^c State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China.

^d School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang 453007, China. *Corresponding author: zkchen@zstu.edu.cn;* jie_wu@fudan.edu.cn

Contents

| 1. General information | 2 |
|---|----|
| 2. General experimental procedure | 3 |
| 3. General procedure for ester-containing phenanthridines | 4 |
| 4. Devices for the photocatalytic reactions | 5 |
| 5. Initial studies and the reaction optimization | 6 |
| 6. Mechanistic study | 7 |
| 7. Characterization of new substrates and all products | 9 |
| 8. References | 20 |
| 9. NMR spectra of compounds | 21 |

1. General information

All glassware was thoroughly oven-dried. Chemicals and solvents were either purchased from commercial suppliers or purified by standard techniques. Thin-layer chromatography plates were visualized by exposure to ultraviolet light and/or staining with phosphomolybdic acid followed by heating on a hot plate. Flash chromatography was carried out using silica gel (200–300 mesh). ¹H NMR and ¹³C NMR spectra were recorded on a Bruker AM-400 (400 MHz). The spectra were recorded in deuterochloroform (CDCl₃) as solvent at room temperature, ¹H and ¹³C NMR chemical shifts are reported in ppm relative to the residual solvent peak. The residual solvent signals were used as references and the chemical shifts were converted to the TMS scale (CDCl₃: $\delta_{\rm H} = 7.26$ ppm, $\delta_{\rm C} = 77.0$ ppm). Data for ¹H NMR are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet, dd = doublet, br = broad), integration, coupling constant (Hz) and assignment. Data for ¹³C NMR are reported as chemical shift. Electrospray–ionisation HRMS data were acquired on a Q–TOF mass spectrometer (Waters SYNAPT G2-Si) LC-MS TOF.

2. General experimental procedure

General procedure for the synthesis of 3PAA2FBN¹



In a flame dried Schlenk flask equipped with a magnetic stir bar diphenylamine (31.25 mmol, 6.25 equiv) were dissolved in dry THF (100 mL) under an atmosphere of N₂. Then, NaH (47 mmol, 9.4 equiv, 60% in oil) were added and the suspension was stirred at 50 °C for 30 minutes. Finally, pentafluorobenzonitrile (5.0 mmol) was added and the resulting mixture was stirred at room temperature for 24 h. The reaction mixture was quenched by the addition of water. After removal of THF, the residue was dissolved in DCM and washed with water. The organic phase was dried over Na₂SO₄ and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography on silica gel.

General procedure for the synthesis of substrates I^2



A solution of related 2-bromo-6-fluorobenzonitrile A (20.0 mmol, 1.0 equiv.), MeNH₂•HCl (30.0 mmol, 1.5 equiv.) and NaOH (30.0 mmol, 1.5 equiv.) in CH₃CN (40 mL) was stirred under air at 80 °C for 12 h. After completion of the reaction, the resulting solution was cooled to room temperature and extracted with EtOAc (100×3 mL), then washed with saturated brine (100 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo to give the intermediate products **B**.

To the above-obtained **B**, substituted phenylboronic acid (15 mmol, 1.5 equiv.), PdCl₂(PPh₃)₂ (0.3 mmol, 0.02 equiv.) and Cs₂CO₃ (42.0 mmol, 2.8 equiv.), were added MeCN (150 mL) and H₂O (7.5 mL). The reaction mixture was stirred at 80 °C under nitrogen atmosphere for 12 h. After completion of the reaction, the resulting solution was cooled to room temperature and extracted with EtOAc (100 × 3 mL). The combined organic layers were washed with saturated brine (100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo to give the crude products **C** without further purification.

To a solution of the above-obtained C (10 mmol) and triethylamine (20 mmol, 2.0 equiv.) in DCM (24 mL) at 0 °C was added related methacryloyl chloride (1.5 equiv) dropwise. The reaction mixture was stirred at 0 °C overnight. After completion of the reaction, the resulting solution was extracted with DCM (30×3 mL) and the combined organic layers were washed with saturated brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography on silica gel using petroleum ether/EtOAc (20:1 to 10:1) as eluent to give the desired substrates 1.

3. General procedure for ester-containing phenanthridines



All optimization reactions were set up in a glove box under N_2 atmosphere. Substrate 1 (0.2 mmol, 1.0 equiv), alkyloxyoxalyl chloride 2 (0.6 mmol, 3.0 equiv) and 2-MePy (0.3 mmol, 1.5 equiv) were added to a solution of photocatalyst 3DPA2FBN (2 mol %)

in dry MeCN (4 mL) at room temperature. The heterogenous mixture was placed in the irradiation apparatus equipped with blue LEDs. The resulting mixture was stirred at room temperature for 12 h. Upon completion of the reaction, the mixture was diluted with ethyl acetate (30 mL), washed with brine (10 ml x 3), dried with Na₂SO₄ and the solvent was evaporated. The crude product was purified by column chromatography on silica gel to afford the desired product **3**.

4. Devices for the photocatalytic reactions

Irradiation of visible light was performed with a 36 W Blue LED strip. All photocatalyzed alkoxycarbonylation/cyclization reactions were carried out at room temperature (r.t.) with fan-assisted cooling to maintain a temperature of approximately 40-45 °C. The distance between tube and lamp was approximately 3 cm. Manufacture of the light source: LED strip Manufacturer: Greethink Model: GT-5050-Blue Wavelength of peak intensity: 460-470 nm Material of the irradiation vessel: borosilicate glass Distance of the irradiation vessel from the light source: approximately 3 cm.

| | CN Me N Me + C 0 1a | Cluco ₂ Et ph | base (1.5 equiv) otocatalyst (2 mol%) solvent, 12 h, rt blue LEDs | Me CO ₂ Et |
|--------------------|------------------------------|--------------------------|--|-------------------------------------|
| Entry ^a | Photocatalyst | Solvent | Base | Yield ^b (3a , %) |
| 1 | Ir(ppy) ₃ | MeCN | 2,6-lutidine | 32% |
| 2 | Ir(ppy)2(dtppy)PF6 | MeCN | 2,6-lutidine | 62% |
| 3 | 3DPA2FBN | MeCN | 2,6-lutidine | 63% |
| 4 | 3DPA2FBN | DCM | 2,6-lutidine | 53% |
| 5 | 3DPA2FBN | DMF | 2,6-lutidine | 47% |
| 6 | 3DPA2FBN | PhCF ₃ | 2,6-lutidine | 38% |
| 7 | 3DPA2FBN | THF | 2,6-lutidine | 31% |
| 8 | 3DPA2FBN | MeCN | 2-MePy | 66% |
| 9 | 3DPA2FBN | MeCN | 2,6-di-tBu-4-MePy | 49% |
| 10 | 3DPA2FBN | MeCN | 2,6-di- ^t BuPy | 58% |
| 11 | 3DPA2FBN | MeCN | 2,4,6-tri-MePy | 58% |
| 12 | 3DPA2FBN | MeCN | 4-MeOPy | 13% |
| 13 | 3DPA2FBN | MeCN | 2-CNPy | 7% |
| 14 | 3DPA2FBN | MeCN | DABCO | 19% |
| 15 | 3DPA2FBN | MeCN | K ₂ HPO ₄ | 25% |
| 16 | 3DPA2FBN | MeCN | K ₂ CO ₃ | 16% |
| 17 | 3DPA2FBN | MeCN | | 11% |
| 18 | | MeCN | 2-MePy | NR |
| 19 ^c | 3DPA2FBN | MeCN | 2-MePy | NR |

5. Initial studies and the reaction optimization.

^{*a*} Unless otherwise noted, reaction conditions are as follows: **1a** (0.2 mmol), **2a** (0.6 mmo l), photocatalyst (0.004 mmol), base (0.3 mmol), solvent (4 mL), blue LEDs, rt, 12 h, un der a N₂ atmosphere. ^{*b*} Yield determined by ¹H NMR analysis using 1,3,5-trimethoxybenze ne as internal standard. ^{*c*} In the dark.



6. Mechanistic study

Cyclic Voltammetry Studies



Figure S1 Cyclic voltammogram of ethyl chlorooxoacetate 2b [0.02 M] in [0.1 M] TBAPF₆ in CH₃CN. Sweep rate: 200 mV/s. Glassy carbon working electrode, Ag/AgCl (satd. KCl) reference electrode, Pt wire auxiliary electrode. Irreversible reduction. $E_p = -1.34$ V.



Figure S2 Cyclic voltammogram of ethyl chlorooxoacetate 2a [0.02 M] and 2-

methylpyridine [0.02 M] in [0.1 M] TBAPF₆ in CH₃CN. Sweep rate: 200 mV/s. Glassy carbon working electrode, Ag/AgCl (satd. KCl) reference electrode, Pt wire auxiliary electrode. Irreversible reduction. $E_p = -1.29$ V;

Stern-Volmer fluorescence quenching experiments

Stern-Volmer fluorescence quenching experiments were run with freshly prepared solutions of 0.1 mM 3DPA2FBN in degassed dry CH₃CN added with the appropriate amount of a quencher in a screw-top quartz cuvette at room temperature. The solutions were irradiated at 370 nm and fluorescence was measured from 400 nm to 600 nm.



Figure S3 Fluorescence quenching experiments of 3DPA2FBN and 2b.



Figure S4 Fluorescence quenching experiments of 3DPA2FBN and **2b** + 2-methylpyridine.



Figure S5 Stern-Volmer plots of 3DPA2FBN with different quenchers.

7. Characterization of new substrates and all products

Ethyl 2-(4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthridin-6-yl)ac etate (3a)



Purification by flash chromatography (PE/EA = 10/1). White solid; mp 89.1–90.3 °C; 64% yield;
¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.51 (d, J = 7.8 Hz, 1H), 8.26 (d, J = 8.2 Hz, 1H), 8.
08 (d, J = 8.2, 0.6 Hz, 1H), 7.82 (t, J = 8.2

Hz, 1H), 7.76–7.68 (m, 1H), 7.65–7.58 (m, 1H), 7.24 (d, J = 8.2 Hz, 1H), 3. 95 (d, J = 17.1 Hz, 1H), 3.91–3.81 (m, 2H), 3.63–3.54 (m, 4H), 1.58 (s, 3H), 0.99 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 174.0, 171.9, 159. 7, 144.7, 138.9, 133.3, 131.7, 129.6, 128.9, 126.4, 122.9, 122.5, 116.0, 111.9, 110.8, 60.4, 48.7, 43.1, 29.9, 29.9, 13.8.; HRMS (ESI) for C₂₁H₂₀N₂O₃Na [M+ Na]⁺ calcd. 371.1366, found 371.1382.

methyl 2-(4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthridin-6yl)acetate (3b)



Purification by flash chromatography (PE/EA = 10/1).White solid; mp 168.9–170.6 °C; 90%; ¹H NMR (400 MHz, CDCl₃) δ 8.51 (d, J = 8.3 Hz, 1H), 8.26 (d, J = 8.2 Hz, 1H), 8.08 (dd, J = 8.2, 1.4 Hz, 1H), 7.82 (t, J =

8.1 Hz, 1H), 7.71 (ddd, J = 8.3, 7.0, 1.4 Hz, 1H), 7.62 (ddd, J = 8.3, 7.0, 1.4 Hz, 1H), 7.27 – 7.23 (m, 1H), 3.99 (d, J = 17.2 Hz, 1H), 3.63 – 3.55 (m, 4H), 3.47 (s, 3H), 1.57 (s, 3H). ¹³**C NMR (100 MHz, CDCl₃)** 173.9, 172.6, 159.6, 144.7, 138.9, 133.4, 131.7, 129.6, 128.9, 126.4, 122.9, 122.6, 116.0, 111.9, 110.9, 51.6, 48.7, 42.7, 29.9, 29.9; $C_{20}H_{18}N_2O_3$ [M+Na]⁺ calcd 357.1210, found 357.1227.

4-phenylbutyl 2-(4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2gh]phenanthridin-6-yl)acetate (3c)



Purification by flash chromatography (PE/EA = 8/1). Yellow oil; 54%; ¹H NMR (400 MHz, Chloroformd) δ 8.49 (dd, J = 8.2, 1.5 Hz, 1H), 8.24 (d, J = 8.3 Hz, 1H), 8.06 (dd, J = 8.1, 1.5 Hz, 1H), 7.80 (t, J = 8.1 Hz, 1H), 7.69 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.61 (ddd, J

= 8.3, 7.0, 1.5 Hz, 1H), 7.25 – 7.12 (m, 4H), 7.06 – 6.98 (m, 2H), 3.96 (d, J = 17.1 Hz, 1H), 3.82 (t, J = 5.9 Hz, 2H), 3.64 – 3.52 (m, 4H), 2.41 (t, J = 7.0 Hz, 2H), 1.56 (d, J = 4.0 Hz, 3H), 1.44 – 1.34 (m, 4H). ¹³**C NMR (100 MHz, CDCl3)** δ 173.9, 172.0, 159.6, 144.6, 141.9, 138.9, 133.3, 131.7, 129.6, 128.9, 128.3, 128.2, 126.4, 125.7, 122.9, 122.5, 116.0, 111.9, 110.8, 77.3, 77.0, 76.7, 64.3, 48.7, 43.0, 35.2, 30.0, 29.9, 27.9, 27.3; C₂₉H₂₈N₂O₃ [M+Na]⁺ calcd 475.1992, found 475.2001.

dodecyl 2-(4,6-*dimethyl-5-oxo-5,6-dihydro-4H-pyrido*[4,3,2-gh]phenanthridin-6yl)acetate (3d)



Purification by flash chromatography (PE/EA = 8/1). Yellow oil; 47%; ¹H NMR (400 MHz, CDCl₃) δ 8.51 (dd, J = 8.2, 1.4 Hz, 1H),

8.26 (d, J = 8.3 Hz, 1H), 8.08 (dd, J = 8.2, 1.3 Hz, 1H), 7.82 (t, J = 8.1 Hz, 1H), 7.71 (ddd, J = 8.3, 6.9, 1.4 Hz, 1H), 7.61 (ddd, J = 8.3, 6.9, 1.4 Hz, 1H), 7.27 – 7.22 (m, 1H), 3.95 (d, J = 17.0 Hz, 1H), 3.80 (t, J = 6.6 Hz, 2H), 3.61 (s, 4H), 1.57 (s, 3H), 1.26 (q, J = 14.8, 10.8 Hz, 14H), 1.05 (d, J = 5.3 Hz, 6H), 0.87 (d, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 173.9, 171.9, 159.7, 144.7, 139.0, 133.4, 131.7, 129.6, 128.9, 126.4, 122.9, 122.5, 116.0, 111.9, 110.8, 64.6, 48.7, 43.0, 31.9, 30.0, 29.9, 29.6, 29.6, 29.5, 29.3, 29.3, 29.1, 28.4, 25.6, 22.7, 14.1; C₃₁H₄₀N₂O₃ [M+Na]⁺ calcd 511.2931, found 511.2947.

((3r,5r,7r)-adamantan-1-yl)methyl 2-(4,6-dimethyl-5-oxo-5,6-dihydro-4Hpyrido[4,3,2-gh]phenanthridin-6-yl)acetate (3e)



Purification by flash chromatography (PE/EA = 15/1). Yellow oil; 82%; ¹H NMR (400 MHz, CDCl₃) δ 8.51 (dd, J = 8.2, 1.4 Hz, 1H), 8.26 (d, J = 8.3 Hz, 1H), 8.08 (d, J = 8.2 Hz, 1H), 7.83 (t, J = 8.1 Hz, 1H), 7.71 (t, J= 7.5 Hz, 1H), 7.65 – 7.58 (m, 1H), 7.29 – 7.21 (m, 1H),

3.99 (d, J = 17.0 Hz, 1H), 3.67 (d, J = 19.6 Hz, 1H), 3.61 (s, 3H), 3.41 (q, J = 10.8 Hz, 2H), 1.70 – 1.63 (m, 4H), 1.51 (d, J = 12.4 Hz, 3H), 1.37 – 1.27 (m, 4H), 1.13 – 1.01 (m, 6H), 0.90 – 0.82 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 173.8, 171.8, 159.6, 139.0, 133.5, 131.8, 129.6, 129.0, 126.5, 122.8, 122.5, 116.0, 111.9, 110.8, 74.0, 48.8, 42.5, 38.6, 36.6, 32.8, 30.2, 29.9, 27.8; C₃₀H₃₂N₂O₃ [M+Na]⁺ calcd 491.2305, found 491.2317.

1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl2-(4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthridin-6-yl)acetate (3f)



Purification by flash chromatography (PE/EA = 10/1). White solid; mp 85–84 °C; 76%; ¹H NMR (400 MHz, CDCl₃) δ 8.51 (dd, *J* = 8.3, 1.4 Hz, 1H), 8.26 (d, *J* = 8.2 Hz, 1H), 8.05 (ddd, *J* = 8.0, 6.4, 1.4 Hz, 1H), 7.83 (t, *J* = 8.1 Hz, 1H), 7.74 – 7.67 (m, 1H), 7.64 – 7.58 (m, 1H), 7.23 (dd, *J* = 7.9, 2.0 Hz, 1H),

4.11 (dd, J = 11.6, 1.9 Hz, 1H), 4.00 (dd, J = 19.7, 17.0 Hz, 1H), 3.73 – 3.58 (m, 4H), 1.55 (d, J = 4.9 Hz, 3H), 1.48 (dt, J = 22.3, 2.6 Hz, 2H), 1.33 (dt, J = 10.3, 2.0 Hz, 1H), 1.30 – 1.20 (m, 2H), 1.12 (dt, J = 6.1, 3.3 Hz, 2H), 0.99 – 0.92 (m, 1H), 0.86 (s, 2H), 0.77 (s, 3H), 0.74 – 0.61 (m, 1H), 0.53 (d, J = 17.2 Hz, 3H), 0.19 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 173.7, 173.6, 172.1, 172.0, 159.6, 159.6, 144.8, 144.7, 139.1, 139.0, 133.5, 133.5, 131.8, 131.8, 129.7, 129.6, 129.0, 129.0, 126.4, 126.4, 122.9, 122.9, 122.5, 116.0, 112.0, 111.9, 110.9, 110.8, 86.6, 86.6, 77.4, 77.3, 77.0, 76.7, 48.8, 48.8, 48.2, 48.1, 48.1, 47.9, 42.4, 42.2, 41.2, 41.1, 39.3, 39.0, 31.6, 30.6, 30.5, 29.9, 29.5, 29.5, 26.1, 26.0, 25.7, 25.5, 22.7, 20.0, 19.6, 19.0, 18.8, 14.1; C₂₉H₃₂N₂O₃ [M+Na]⁺ calcd 479.2305, found 479.2307. (1R,2R,5S)-2-isopropyl-5-methylcyclohexyl 2-(4,6-dimethyl-5-oxo-5,6-dihydro-4Hpyrido[4,3,2-gh]phenanthridin-6-yl)acetate (3g)



Purification by flash chromatography (PE/EA = 10/1). White solid; mp 103–105 °C; 34%; ¹H NMR (400 MHz, CDCl₃) δ 8.51 (dt, *J* = 8.2, 2.1 Hz, 2H), 8.26 (dd, *J* = 8.3, 6.3 Hz, 2H), 8.06 (ddd, *J* = 9.6, 8.1, 1.3 Hz, 2H), 7.83 (td, *J* = 8.1, 4.1 Hz, 2H), 7.71 (ddt, *J* = 8.4, 6.9, 1.6 Hz, 2H), 7.61 (ddt,

J= 8.4, 7.1, 1.5 Hz, 2H), 7.24 (d, J= 7.9 Hz, 2H), 4.34 (dtd, J= 18.5, 10.9, 4.4 Hz, 2H), 3.94 (d, J = 17.0 Hz, 1H), 3.83 (d, J = 16.7 Hz, 1H), 3.69 – 3.55 (m, 8H), 1.59 (d, J = 9.9 Hz, 7H), 1.46 (tt, J = 11.7, 2.5 Hz, 4H), 1.30 – 1.12 (m, 4H), 0.90 – 0.81 (m, 4H), 0.71 (d, J= 6.5 Hz, 4H), 0.67 (dd, J= 6.7, 1.4 Hz, 6H), 0.59 (td, J = 12.1, 11.7, 3.9 Hz, 4H), 0.32 (d, J = 6.9 Hz, 3H), 0.19 (d, J = 7.0 Hz, 3H), 0.13 (d, J = 6.9 Hz, 3H); ¹³**C NMR (100 MHz, CDCl**₃) δ 174.0, 173.8, 171.5, 170.9, 159.9, 159.9, 144.7, 139.1, 139.0, 133.5, 133.4, 131.8, 131.7, 129.6, 129.0, 128.9, 126.5, 126.5, 122.9, 122.9, 122.5, 122.5, 116.0, 115.9, 112.1, 112.0, 110.8, 110.7, 77.4, 77.2, 77.0, 76.7, 74.1, 74.1, 48.8, 48.8, 47.0, 46.8, 43.8, 43.6, 40.6, 40.4, 34.1, 31.2, 31.1, 30.0, 30.0, 29.9, 29.7, 25.8, 25.2, 23.2, 22.7, 21.9, 21.8, 20.7, 20.3, 15.6, 15.5; C₂₉H₃₄N₂O₃ [M+Na]⁺ calcd 481.2462, found 481.2472.

(S)-2-(1,3-dioxo-2,3-dihydro-1H-inden-2-yl)-3,3-dimethylbutyl 2-(4,6-dimethyl-5oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthridin-6-yl)acetate (3h)



Purification by flash chromatography (PE/EA = 2/1). Yellow oil; 86%; ¹H NMR (100 MHz, CDCl₃) δ 8.46 (dt, J = 8.5, 1.8 Hz, 1H), 8.19 (d, J = 8.3 Hz, 1H), 7.99 (dd, J = 57.6, 8.1 Hz, 1H), 7.82 – 7.68 (m, 6H), 7.61 (ddd, J = 8.4, 6.9, 1.6 Hz, 1H), 7.22 (dd, J = 8.0, 4.1 Hz, 1H), 4.75 (dt,

J = 16.4, 11.1 Hz, 1H), 4.36 (ddd, *J* = 20.7, 11.5, 4.1 Hz, 1H), 4.17 – 4.11 (m, 1H), 3.84

(dd, J = 17.2, 14.6 Hz, 1H), 3.60 – 3.39 (m, 4H), 1.45 (d, J = 6.9 Hz, 3H), 1.28 – 1.23 (m, 1H), 0.94 – 0.89 (m, 9H); ¹³**C NMR** (100 MHz, CDCl₃) δ 173.6, 173.5, 171.7, 171.7, 168.9, 168.9, 168.6, 168.6, 159.3, 159.3, 144.6, 138.8, 133.9, 133.8, 133.7, 133.7, 133.3, 131.8, 131.7, 131.3, 131.2, 129.7, 129.6, 129.0, 128.9, 128.8, 128.5, 126.4, 123.3, 123.3, 123.1, 123.0, 122.8, 122.8, 122.5, 116.0, 115.9, 111.7, 110.9, 110.8, 60.4, 60.4, 59.1, 59.0, 48.6, 48.6, 42.4, 42.2, 35.2, 35.1, 29.9, 29.9, 29.8, 27.7, 27.7; C₃₁H₄₀N₂O₃ [M+Na]⁺ calcd 511.2931, found 511.2947.

(3S,8R,9S,10S,13S,14S)-10,13-dimethyl-17-oxohexadecahydro-1H-

cyclopenta[a]phenanthren-3-yl 2-(4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2gh]phenanthridin-6-yl)acetate (3i)



Purification by flash chromatography (PE/EA = 2/1). Colourless oil; 91%; ¹H NMR (400 MHz, CDCl₃) δ 8.52 (d, *J* = 8.2 Hz, 1H), 8.27 (d, *J* = 8.3 Hz, 1H), 8.09 (s, 1H), 7.83 (t, *J* = 8.1 Hz, 1H), 7.72 (t, *J* = 7.6 Hz, 1H), 7.63 (t, *J* = 7.6 Hz, 1H), 7.26 (d, *J* = 3.3 Hz, 1H), 4.36 (m, 1H), 3.91 (d, *J* = 16.9 Hz, 1H), 3.65 (d,

J = 34.2 Hz, 4H), 2.39 (dd, J = 19.4, 9.0 Hz, 1H), 2.00 (dd, J = 19.1, 9.3 Hz, 1H), 1.89 - 1.67 (m, 4H), 1.51 (td, J = 9.2, 8.5, 3.8 Hz, 3H), 1.43 - 1.38 (m, 2H), 1.29 - 1.20 (m, 3H), 1.09 (ddd, J = 27.7, 14.4, 8.5 Hz, 4H), 0.89 - 0.73 (m, 9H), 0.63 (d, J = 8.7 Hz, 3H), 0.54 (d, J = 11.1 Hz, 1H); ¹³**C NMR (100 MHz, CDCl₃)** δ 221.2, 173.9, 171.2, 133.4, 128.9, 128.7, 128.5, 126.5, 122.8, 122.5, 122.5, 116.0, 112.0, 110.8, 73.5, 54.0, 51.2, 48.7, 47.6, 44.3, 43.8, 36.4, 35.7, 35.3, 34.8, 33.5, 31.4, 30.6, 29.9, 29.8, 27.9, 26.9, 21.6, 20.3, 13.7, 11.9; C₂₉H₃₂N₂O₃ [M+Na]⁺ calcd 615.3193, found 615.3204.

methyl 2-(4,6,9-trimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthridin-6yl)acetate (4a)

Purification by flash chromatography (PE/EA = 6/1). White solid; mp 203–205 °C; 50%; ¹H NMR (400 MHz, CDCl₃) δ 8.39 (d, J = 8.3 Hz, 1H), 8.21 (d, J = 8.3 Hz, 1H), 7.88 (s, 1H), 7.79 (t, J = 8.1 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.21 (d, J = 8.0 Hz, 1H),



3.97 (d, J = 17.2 Hz, 1H), 3.58 (d, J = 20.2 Hz, 4H),3.46 (s, 3H), 2.57 (s, 3H), 1.56 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 173.9, 172.6, 159.5, 144.8, 139.2, 138.9, 133.4, 131.7, 129.1, 128.2, 122.3,

120.6, 115.9, 111.6, 110.4, 51.6, 48.6, 42.6, 29.9, 29.9, 21.5; C₂₁H₂₀N₂O₃ [M+Na]⁺ calcd 371.1366, found 371.1380.

Methyl 2-(9-methoxy-4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-

gh]phenanthridin-6-yl)acetate (4b)



Purification by flash chromatography (PE/EA = 8/1). White solid; mp 81-83 °C; 61%; ¹H NMR (**400 MHz, CDCl**₃) δ 8.39 (d, *J* = 9.1 Hz, 1H), 8.15 (d, J = 8.3 Hz, 1H), 7.78 (t, J = 8.1 Hz, 1H), 7.47 (s,

1H), 7.29 – 7.22 (m, 1H), 7.17 (d, J = 7.9 Hz, 1H), 3.99 (s, 4H), 3.61 (s, 4H), 3.48 (s, 3H), 1.57 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 173.9, 172.5, 160.3, 160.0, 146.4, 138.9, 133.6, 131.8, 123.8, 117.7, 117.0, 115.6, 111.1, 109.8, 109.2, 55.5, 51.6, 48.6, 42.7, 30.0, 29.9; C₂₁H₂₀N₂O₄ [M+Na]⁺ calcd 387.1315, found 387.1324.

methyl

2-(9-(tert-butyl)-4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2gh]phenanthridin-6-yl)acetate (4c)



Purification by flash chromatography (PE/EA = 2/1). White solid; mp 192–193 °C; 62%; ¹H NMR (400 **MHz, CDCl**₃) δ 8.44 (d, *J* = 8.7 Hz, 1H), 8.22 (d, *J* = 8.3 Hz, 1H), 8.05 (d, J = 2.1 Hz, 1H), 7.79 (t, J = 8.1

Hz, 1H), 7.70 (dd, *J* = 8.7, 2.1 Hz, 1H), 7.21 (d, *J* = 7.9 Hz, 1H), 4.00 (d, *J* = 17.2 Hz, 1H), 3.61 (s, 4H), 3.48 (s, 3H), 1.47 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 174.0, 172.6, 159.4, 152.3, 144.7, 138.8, 133.3, 131.6, 125.4, 124.8, 122.2, 120.5, 115.9, 111.7, 110.4, 51.6, 48.6, 42.7, 35.0, 31.3, 30.0, 29.8; C₂₄H₂₇N₂O₃ [M+Na]⁺ calcd 413.1836, found 413.1859.

methyl 2-(4,6-dimethyl-5-oxo-9-phenyl-5,6-dihydro-4H-pyrido[4,3,2-

gh]phenanthridin-6-yl)acetate (4d)



Purification by flash chromatography (PE/EA = 2/1). White solid; mp 226–228 °C; 52%; ¹H NMR (400 MHz, CDCl₃) δ 8.56 (d, *J* = 8.6 Hz, 1H), 8.32 (d, *J* = 1.9 Hz, 1H), 8.26 (d, *J* = 8.3 Hz, 1H), 7.91 – 7.75 (m,

4H), 7.50 (dd, J = 8.4, 6.9 Hz, 2H), 7.41 (d, J = 7.3 Hz, 1H), 7.27 – 7.23 (m, 1H), 4.00 (d, J = 17.2 Hz, 1H), 3.65 – 3.56 (m, 4H), 3.48 (s, 3H), 1.59 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 173.9, 172.6, 160.1, 145.0, 141.7, 140.2, 139.0, 133.2, 131.9, 128.9, 127.7, 127.5, 127.4, 125.6, 123.1, 122.0, 116.1, 111.9, 110.9, 51.7, 48.7, 42.7, 29.9, 29.9; C₂₆H₂₂N₂O₃ [M+Na]⁺ calcd 433.1523, found 433.1530.

methyl 2-(9-fluoro-4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-

gh]phenanthridin-6-yl)acetate (4e)



Purification by flash chromatography (PE/EA = 6/1). White solid; mp 173–175 °C; 33%; ¹H NMR (400 MHz, CDCl₃) δ 8.48 (dd, J = 9.1, 5.9 Hz, 1H), 8.18 (d, J = 8.3 Hz, 1H), 7.83 (t, J = 8.1 Hz, 1H), 7.73 (dd, J =

9.9, 2.7 Hz, 1H), 7.37 (td, J = 8.6, 2.6 Hz, 1H), 7.28 – 7.21 (m, 1H), 3.96 (d, J = 17.2 Hz, 1H), 3.61 (s, 4H), 3.49 (s, 3H), 1.57 (s, 3H); ¹³**C NMR (100 MHz, CDCl**₃) δ 173.7, 172.6, 163.4(d, J = 247 Hz), 161.1, 139.1, 133.2, 132.2, 124.6(d, J = 10 Hz), 119.7, 119.6, 115.8, 115.6(d, J = 24 Hz), 115.5, 114.0(d, J = 20 Hz), 111.5, 110.7, 51.7, 48.7, 42.6, 29.9, 29.9; C₂₀H₁₇N₂O₃F [M+Na]⁺ calcd 375.1115, found 375.1131.

methyl

2-(9-chloro-4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-

gh]phenanthridin-6-yl)acetate (4f)



Purification by flash chromatography (PE/EA = 8/1). White solid; mp 168–170 °C; 63%; ¹H NMR (400 MHz, CDCl₃) δ 8.40 (d, J = 8.8 Hz, 1H), 8.18 (d, J = 8.3 Hz, 1H), 8.07 (d, J = 2.2 Hz, 1H), 7.82 (t, J = 8.1 Hz, 1H), 7.55 (dd, J = 8.8, 2.3 Hz, 1H), 7.45 (s, 1H), 7.25 (d, J = 7.9 Hz, 1H), 3.94 (d, J = 17.3 Hz, 1H), 3.61 (s, 3H), 3.55 (d, J = 13.3 Hz, 1H), 3.48 (s, 3H), 1.56 (s, 3H). ¹³C **NMR (100 MHz, CDCl₃)** δ 180.0, 173.7, 172.6, 170.0, 161.1, 146.9, 145.3, 144.7, 139.1, 136.6, 134.9, 134.6, 133.7, 133.0, 132.2, 130.3, 128.8, 128.8, 127.0, 125.7, 123.9, 123.4, 121.4, 116.4, 115.9, 111.8, 111.1, 51.9, 51.7, 48.7, 44.1, 42.6, 41.1, 29.9, 29.8, 28.3, 24.2; C₂₀H₁₇N₂O₃Cl [M+Na]⁺ calcd 391.0820, found 391.0827.

methyl 2-(9-bromo-4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2gh]phenanthridin-6-yl)acetate (4g)



Purification by flash chromatography (PE/EA = 8/1). White solid; mp 196–198 °C; 39%; ¹H NMR (400 MHz, CDCl₃) δ 8.34 (d, J = 8.8 Hz, 1H), 8.26 (d, J = 2.1 Hz, 1H), 8.22 – 8.16 (m, 1H), 7.83 (t, J = 8.2 Hz,

1H), 7.69 (dd, J = 8.7, 2.1 Hz, 1H), 7.64 (d, J = 7.1 Hz, 1H), 3.94 (d, J = 17.2 Hz, 1H), 3.61 (s, 3H), 3.49 (s, 4H), 1.56 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 173.7, 172.6, 161.1, 145.5, 139.1, 133.0, 132.3, 132.0, 132.0, 129.6, 128.9, 124.1, 123.3, 122.8, 121.8, 116.1, 115.9, 111.9, 111.2, 51.7, 48.8, 42.6, 29.9, 29.9; C₂₀H₁₇N₂O₃Br [M+Na]⁺ calcd 435.0315, found 435.0326.

methyl

2-(9-cyano-4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-

gh]phenanthridin-6-yl)acetate (4h)

Purification by flash chromatography (PE/EA = 6/1). White solid; mp 220–221 °C; 45%; ¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, *J* = 8.5 Hz, 1H), 8.42 (d, *J* = 1.7 Hz, 1H), 8.26 (d, *J* = 8.2 Hz, 1H), 7.92 (t, *J* = 8.1 Hz, 1H), 7.79 (dd, *J* = 8.5, 1.8 Hz, 1H), 7.37 (d, *J* = 8.0 Hz, 1H), 3.95 (d, *J* = 17.3 Hz, 1H), 3.66 – 3.58 (m, 4H), 3.50 (s, 3H), 1.57 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 173.5, 172.6, 162.2, 143.9, 139.3, 134.7, 132.7,



132.3, 129.8, 127.8, 126.2, 124.0, 118.6, 116.3, 112.6, 112.2, 51.7, 48.9, 42.6, 30.0, 29.8; C₂₁H₁₇N₃O₃ [M+Na]⁺ calcd 382.1162, found 382.1174.

methyl 2-(4,6-dimethyl-5-oxo-9-(trifluoromethyl)-5,6-dihydro-4H-pyrido[4,3,2gh]phenanthridin-6-yl)acetate (4i)



Purification by flash chromatography (PE/EA = 4/1). White solid; mp 210–211 °C; 64%; ¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, *J* = 8.6 Hz, 1H), 8.38 (d, *J* = 1.9 Hz, 1H), 8.29 (d, *J* = 8.2 Hz, 1H), 7.90 (t, *J* = 8.1

Hz, 1H), 7.81 (dd, J = 8.6, 1.9 Hz, 1H), 7.34 (d, J = 8.1 Hz, 1H), 3.97 (d, J = 17.3 Hz, 1H), 3.65 – 3.58 (m, 4H), 3.49 (s, 3H), 1.58 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 173.6, 172.6, 161.5, 144.0, 139.2, 132.5, 130.9, 130.6, 127.2 (q, J = 4 Hz), 125.2 (q, J = 271 Hz), 123.7, 122.3 (q, J = 3 Hz), 116.3, 112.5, 112.0, 51.7, 48.8, 42.7, 30.0, 29.9; C₂₁H₁₇N₂O₃F₃ [M+Na]⁺ calcd 425.1083, found 425.1096.

methyl 2-(4,6,10-trimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthridin-6yl)acetate (4j)



Purification by flash chromatography (PE/EA = 8/1). White solid; mp 123–124 °C; 45%; ¹H NMR (400 MHz, CDCl₃) δ 8.38 (d, *J* = 8.1 Hz, 1H), 8.26 (d, *J* = 8.3 Hz, 1H), 7.81 (t, *J* = 8.1 Hz, 1H), 7.58 (d, *J* = 7.1

Hz, 1H), 7.51 (t, J = 7.6 Hz, 1H), 7.28 – 7.20 (m, 1H), 3.96 (d, J = 17.0 Hz, 1H), 3.47 (s, 3H), 2.81 (s, 3H), 1.57 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 174.0, 172.6, 158.0, 143.3, 138.9, 137.4, 133.7, 131.5, 129.5, 126.1, 122.7, 120.4, 116.3, 111.7, 110.6, 51.6, 48.9, 42.8, 30.3, 29.9, 18.2; C₂₁H₂₀N₂O₃ [M+Na]⁺ calcd 371.1366, found 371.1382.

methyl 2-(4,6,8,10-tetramethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2gh]phenanthridin-6-yl)acetate (4k)



Purification by flash chromatography (PE/EA = 8/1). White solid; mp 152–154 °C; 60%; ¹H NMR (400 MHz, CDCl₃) δ 8.23 (d, *J* = 8.3 Hz, 1H), 8.15 (s, 1H), 7.77 (t, *J* = 8.1 Hz, 1H), 7.42 (s, 1H), 7.21 (d, *J* = 7.9

Hz, 1H), 3.94 (d, *J* = 17.0 Hz, 1H), 3.61 (s, 4H), 3.46 (s, 3H), 2.77 (s, 3H), 2.56 (s, 3H), 1.56 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 174.1, 172.6, 156.9, 141.6, 138.8, 137.0, 135.8, 133.4, 131.3, 131.3, 122.5, 119.8, 116.3, 111.7, 110.5, 51.5, 48.8, 42.8, 30.3, 29.8, 21.9, 18.1; C₂₂H₂₂N₂O₃ [M+Na]⁺ calcd 385.1523, found 385.1541.

methyl 2-(4,6-dimethyl-5-oxo-5,6-dihydro-4H-benzo[c]pyrido[4,3,2gh]phenanthridin-6-yl)acetate (4l)



Purification by flash chromatography (PE/EA = 8/1). Yellow oil; 78%; ¹H NMR (400 MHz, CDCl₃) δ 9.05 (d, J = 8.4 Hz, 1H), 8.77 (d, J = 8.6 Hz, 1H), 8.01 (s, 3H), 7.85 (t, J = 8.2 Hz, 1H), 7.74 – 7.60 (m,

2H), 7.30 - 7.23 (m, 1H), 4.01 (d, J = 17.1 Hz, 1H), 3.66 (s, 3H), 3.62 (d, J = 17.1 Hz, 1H), 3.48 (s, 3H), 1.60 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 173.8, 172.6, 158.7, 144.6, 138.7, 133.4, 133.0, 131.4, 129.9, 129.8, 128.7, 128.2, 127.5, 126.5, 126.2, 120.9, 119.4, 113.2, 110.1, 51.6, 48.4, 42.7, 30.0, 29.9; C₂₄H₂₀N₂O₃ [M+H]⁺ calcd 385.1547, found 385.1556.

methyl 2-(4-ethyl-6-methyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthridin-6yl)acetate (4m)



Purification by flash chromatography (PE/EA = 8/1). White solid; mp 150–152 °C; 76%; ¹H NMR (400 MHz, CDCl₃) δ 8.50 (d, *J* = 8.2 Hz, 1H), 8.24 (d, *J* = 8.3 Hz, 1H), 8.07 (d, *J* = 7.9 Hz, 1H), 7.82 (t, *J* = 8.1 Hz, 1H),

7.71 (t, J = 7.5 Hz, 1H), 7.61 (t, J = 7.6 Hz, 1H), 7.27 (d, J = 8.3 Hz, 1H), 4.26 (q, J = 7.1 Hz, 2H), 3.98 (d, J = 17.2 Hz, 1H), 3.58 (d, J = 17.1 Hz, 1H), 3.46 (s, 3H), 1.56 (s, 3H), 1.36 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 173.4, 172.5, 159.7, 137.7,

133.7, 131.8, 129.6, 128.9, 128.6, 126.4, 123.0, 122.5, 115.8, 112.2, 110.8, 51.6, 48.5, 42.6, 37.3, 29.8, 11.9; C₂₁H₂₀N₂O₃ [M+Na]⁺ calcd 371.1366, found 371.1383.

8. References

- 1 E. Speckmeier, T. G. Fischer and K. Zeitler, A toolbox approach to construct broadly applicable metal-free catalysts for photoredox chemistry: deliberate tuning of redox potentials and importance of halogens in donor–acceptor cyanoarenes, J. Am. Chem. Soc., 2018, 140, 15353–15365.
- 2 (a) X. Li, X. Fang, S. Zhuang, P. Liu and P. Sun, Photoredox catalysis: construction of polyheterocycles via alkoxycarbonylation/ addition/ cyclization sequence, *Org. Lett.*, 2017, **19**, 3580–3583; (b) J.-Q. Shang, S.-S. Wang, H. Fu, Y. Li, T. Yang and Y.-M. Li, Oxidative radical cascade cyclization involving C(sp³)–C(sp³), C(sp³)–C(sp²) and C(sp²)–N bonds formation: direct construction of cyano and methyl substituted polyheterocycles, *Org. Chem. Front.*, 2018, **5**, 1945–1949.

9. NMR spectra of compounds

Ethyl 2-(4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthridin-6-yl)ac etate (3a)





210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)

methyl 2-(4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthridin-6-yl) acetate (3b)





f1 (ppm)

4-phenylbutyl 2-(4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthridi

n-6-yl)acetate (3c)





dodecyl 2-(4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthridin-6-yl) acetate (3d)



((3r,5r,7r)-adamantan-1-yl)methyl 2-(4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4, 3,2-gh]phenanthridin-6-yl)acetate (3e)

8.55 **8**.55 **8**.55 **8**.55 **8**.55 **8**.55 **8**.55 **8**.55 **8**.27 **7**.75 **8**.27 **7**.75 **8**.27 **7**.75 **8**.27 **7**.75 **8**.27 **7**.25 **5**.55 **1**.57 **7**.25 **5**.55 **1**.57 **7**.25 **5**.55 **1**.57 **7**.25 **5**.55 **1**.57 **7**.25 **5**.55 **1**.57 **7**.25 **5**.55 **1**.57 **7**.25 **5**.55 **1**.57 **7**.25 **5**.55 **1**.57 **7**.25 **5**.55 **1**.57 **7**.25 **5**.55 **1**.57 **7**.25 **5**.55 **1**.57 **7**.25 **5**.55 **1**.57 **7**.25 **5**.55 **1**.57 **7**.25 **5**.55 **1**.57 **7**.25 **5**.55 **1**.57 **1**



f1 (ppm)

1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl 2-(4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyri do[4,3,2-gh]phenanthridin-6-yl)acetate (3f)



(1R,2R,5S)-2-isopropyl-5-methylcyclohexyl 2-(4,6-dimethyl-5-oxo-5,6-dihydro-4H -pyrido[4,3,2-gh]phenanthridin-6-yl)acetate (3g)



f1 (ppm)

(S)-2-(1,3-dioxo-2,3-dihydro-1H-inden-2-yl)-3,3-dimethylbutyl 2-(4,6-dimethyl-5-o xo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthridin-6-yl)acetate (3h)



f1 (ppm)

(3S,8R,9S,10S,13S,14S)-10,13-dimethyl-17-oxohexadecahydro-1H-cyclopenta[a]ph enanthren-3-yl 2-(4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthrid in-6-yl)acetate (3i)



f1 (ppm)



methyl 2-(4,6,9-trimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthridin-6-y



Methyl 2-(9-methoxy-4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenant hridin-6-yl}acetate (4b)

210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)



methyl 2-(9-(*tert-butyl*)-4,6-*dimethyl*-5-*oxo*-5,6-*dihydro*-4*H*-*pyrido*[4,3,2-*gh*]*phena nthridin*-6-*yl*)*acetate* (4*c*)



methyl 2-(4,6-dimethyl-5-oxo-9-phenyl-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthri din-6-yl)acetate (4d)



methyl 2-(9-fluoro-4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthri din-6-yl)acetate (4e)



methyl 2-(9-chloro-4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthri din-6-yl)acetate (4f)



methyl 2-(9-bromo-4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthri



methyl 2-(9-cyano-4,6-dimethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthri din-6-yl)acetate (4h)

210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)











methyl 2-(4,6,8,10-tetramethyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthridi

2-(4,6-dimethyl-5-oxo-5,6-dihydro-4H-benzo[c]pyrido[4,3,2-

gh]phenanthridin-6-yl)acetate (4l)

methyl



210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)



methyl 2-(4-ethyl-6-methyl-5-oxo-5,6-dihydro-4H-pyrido[4,3,2-gh]phenanthridin-6